Evonik to invest USD 100 million to upgrade pharma API CDMO plant in Lafayette, Indiana

  • Evonik Industries AG to invest USD 100 million over five years to modernize active pharmaceutical ingredient production at its Tippecanoe site in Lafayette, Indiana.
  • Upgrade targets higher automation, efficiency, and ergonomics to expand US CDMO capacity for increasingly complex small-molecule APIs.
  • Project positioned as a key step in Evonik’s Next Generation Technologies strategy, aiming to support cost leadership and cut greenhouse-gas emissions.
  • Tippecanoe is Evonik’s second-largest US site, with 170 m³ HPAPI capacity and 860 m³ reactor capacity for general APIs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evonik Industries AG published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.